Screener / SEC EDGAR /CIK 0001237831 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Globus Medical Inc GMED

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What GMED's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 5, 2026, GMED reported $1.04 per share under GAAP and $1.23 on its own adjusted basis: the adjusted number is +18% above GAAP.

GAAP EPS $0.11, release Feb 20, 2024: of 124.6%, or 123.8% on a constant currency basis · GAAP net income for the quarter was $15.0 million · GAAP diluted earnings per share (“EPS”) was $0.11 and non-GAAP diluted EPS was $0.60 · No Adjusted EPS $0.60, release Feb 20, 2024: basis · GAAP net income for the quarter was $15.0 million · GAAP diluted earnings per share (“EPS”) was $0.11 and non-GAAP diluted EPS was $0.60 · Non-GAAP adjusted EBITDA was $170.0 m +446% 2024-02 GAAP EPS $-0.05, release May 7, 2024: of 119.3%, or 119.8% on a constant currency basis · GAAP net loss for the quarter was $7.1 million · GAAP diluted earnings per share (“EPS”) was ($0.05) and non-GAAP diluted EPS was $0.72 · No Adjusted EPS $0.72, release May 7, 2024: basis · GAAP net loss for the quarter was $7.1 million · GAAP diluted earnings per share (“EPS”) was ($0.05) and non-GAAP diluted EPS was $0.72 · Non-GAAP adjusted EBITDA was $166.6 m 2024-05 GAAP EPS $0.23, release Aug 6, 2024: of 115.9% or 117.3% on a constant currency basis · GAAP net income for the quarter was $31.8 million · GAAP diluted earnings per share (“EPS”) was $0.23 and non-GAAP diluted EPS was $0.75 · No Adjusted EPS $0.75, release Aug 6, 2024: basis · GAAP net income for the quarter was $31.8 million · GAAP diluted earnings per share (“EPS”) was $0.23 and non-GAAP diluted EPS was $0.75 · Non-GAAP adjusted EBITDA was $190.4 m +226% 2024-08 GAAP EPS $0.38, release Nov 5, 2024: sales were $625.7 million, an increase of 63.1% · GAAP net income for the quarter was $51.8 million · GAAP diluted earnings per share (“EPS”) was $0.38 and non-GAAP diluted EPS was $0.83 · No Adjusted EPS $0.83, release Nov 5, 2024: 63.1% · GAAP net income for the quarter was $51.8 million · GAAP diluted earnings per share (“EPS”) was $0.38 and non-GAAP diluted EPS was $0.83 · Non-GAAP adjusted EBITDA was $193.7 m +118% 2024-11 GAAP EPS $0.19, release Feb 20, 2025: an increase of 6.9% on a constant currency basis · GAAP net income for the quarter was $26.5 million · GAAP diluted earnings per share (“EPS”) was $0.19 and non-GAAP diluted EPS was $0.84 · No Adjusted EPS $0.84, release Feb 20, 2025: basis · GAAP net income for the quarter was $26.5 million · GAAP diluted earnings per share (“EPS”) was $0.19 and non-GAAP diluted EPS was $0.84 · Non-GAAP adjusted EBITDA was $196.9 m +342% 2025-02 GAAP EPS $0.54, release May 8, 2025: or a decrease of 0.8% on a constant currency basis · GAAP net income for the quarter was $75.5 million · GAAP diluted earnings per share (“EPS”) was $0.54 and non-GAAP diluted EPS was $0.68 “Our Adjusted EPS $0.68, release May 8, 2025: basis · GAAP net income for the quarter was $75.5 million · GAAP diluted earnings per share (“EPS”) was $0.54 and non-GAAP diluted EPS was $0.68 “Our first quarter results were impacte +26% 2025-05 GAAP EPS $1.49, release Aug 7, 2025: an increase of 17.6% on a constant currency basis · GAAP net income for the quarter was $202.8 million · GAAP diluted earnings per share (“EPS”) was $1.49 and non-GAAP diluted EPS was $0.86 “ Q2 Adjusted EPS $0.86, release Aug 7, 2025: basis · GAAP net income for the quarter was $202.8 million · GAAP diluted earnings per share (“EPS”) was $1.49 and non-GAAP diluted EPS was $0.86 “ Q2 results were led by our US Spine b -42% 2025-08 GAAP EPS $0.88, release Nov 6, 2025: an increase of 6.5% on a constant currency basis · GAAP net income for the quarter was $119.0 million · GAAP diluted earnings per share (“EPS”) was $0.88 and non-GAAP diluted EPS was $1.18, inc Adjusted EPS $1.18, release Nov 6, 2025: basis · GAAP net income for the quarter was $119.0 million · GAAP diluted earnings per share (“EPS”) was $0.88 and non-GAAP diluted EPS was $1.18, increasing 134.0% and 42.6%, respectiv +34% 2025-11 GAAP EPS $1.03, release Feb 24, 2026: GAAP diluted earnings per share (“EPS”) was $1.03, an increase of 442.6%. Adjusted EPS $1.28, release Feb 24, 2026: Non- GAAP diluted EPS was $1.28, an increase of 52.1%. +24% 2026-02 GAAP EPS $0.90, release May 7, 2026: GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%. Adjusted EPS $1.12, release May 7, 2026: Non- GAAP diluted EPS was $1.12, an increase of 64.7%. +24% 2026-05 GAAP EPS $1.10, release Aug 6, 2026: GAAP diluted earnings per share (“EPS”) was $1.10, a decrease of 26.2%, primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition. Adjusted EPS $1.34, release Aug 6, 2026: Non-GAAP diluted EPS was $1.34, an increase of 55.8%. +22% 2026-08 GAAP EPS $1.04, release Nov 5, 2026: GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. Adjusted EPS $1.23, release Nov 5, 2026: Non- GAAP diluted EPS was $1.23, an increase of 4.4%. +18% 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. release
Non- GAAP diluted EPS was $1.23, an increase of 4.4%. release

What the company says its adjusted numbers leave out:

In addition, for the period ended September 30, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non- recurring tax adjustments, and the tax effects of all of the foregoing adjustments. release Nov 5, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million

Open on SEC

Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program AUDUBON, PA., November 5, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.

• Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of 0.5% on a constant currency basis.

• Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an increase of 3.0%, as reported.

• GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. Non- GAAP diluted EPS was $1.23, an increase of 4.4%.

• GAAP gross profit as a percentage of net sales was 66.7%, an increase of 2.5%. Non-GAAP adjusted Gross Profit as a percentage of sales was 69.5%, an increase of 1.4%. “Third quarter revenue finished at $764 million, down slightly from the prior year quarter,” commented Keith Pfeil, President and Chief Executive Officer. “U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter. On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation. Our Enabling Technologies strategy continued to make progress, delivering revenue growth of 24%, while simultaneously deploying 73% more robot and navigation units as compared to the prior year quarter, reflecting continued strong demand for our technology and execution against our capital deployment plan. We remain focused on our long-term strategy of achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence ecosystem.”

“Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation,” said Kyle Kline, Chief Financial Officer. “Our performance reflects disciplined execution across the business, which positions us to deliver sustained earnings growth, cash generation, and enhanced shareholder returns. To further this commitment, our Board has authorized a $500 million increase to our existing share repurchase program, which reflects confidence in our long-term growth profile and underlying earnings and cash generation prowess.”

Worldwide net sales for the third quarter of 2026 were $763.7 million, an as- reported decrease of 0.7% over the third quarter of 2025. U.S. net sales for the third quarter of 2026 increased by 0.5% compared to the third quarter of 2025. International net sales decreased by 5.7% over the third quarter of 2025 on an as-reported basis and decreased by 5.0% on a constant currency basis.

GAAP net income for the third quarter of 2026 was $141.2 million, an increase of 18.7% over the same period in the prior year. The increase in GAAP net income was primarily driven by the decrease in cost of sales and operating expenses, decreasing $19.6 million and $25.9 million, respectively, in comparison to the third quarter of 2025. GAAP diluted EPS for the third quarter was $1.04, compared to $0.88 for the third quarter of 2025, an increase of 18.2%. Non-GAAP diluted EPS for the third quarter of 2026, which excludes, among other costs, amortization of intangibles, merger and acquisition-related costs, and restructuring-related costs, was $1.23, compared to $1.18 in the third quarter of 2025, an increase of 4.4%.

The Company is updating its guidance for full-year 2026 revenue to $3.09 billion from the previous range of $3.18 billion to $3.22 billion, representing 5.1% revenue growth as compared to fiscal 2025. The Company reaffirms its full-year fiscal 2026 non-GAAP fully diluted EPS guidance to be in the range of $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully diluted EPS.

Globus Medical will hold a teleconference to discuss its 2026 third quarter results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news- events/events-webcasts.

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.

Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.

To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), management uses certain non- GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, merger and acquisition related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, and gains and losses from strategic investments, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represent the change in fair value of business- acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, legal and tax fees for legal entity reorganization and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.

In addition, for the period ended September 30, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non- recurring tax adjustments, and the tax effects of all of the foregoing adjustments. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present non-GAAP adjusted gross profit, which excludes the impacts of any inventory acquisition- related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends.

Additionally, for the period ended September 30, 2026 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates. We are also presenting base business sales and revenue growth, excluding the contribution from Nevro Corp. (“Nevro”), which we acquired in 2025. We believe these provide insight to how the Company is performing without the impact of the Nevro acquisition.

Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP adjusted gross profit, free cash flow, constant currency net sales growth, base business revenue growth, and day-adjusted basis sales are not calculated in conformity with GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of these non-GAAP measures may differ from that of other companies and therefore may not be comparable. The tables included in this release reconcile the GAAP financial measures to the non-GAAP financial measures discussed above for the three and nine months ended September 30, 2026 and 2025.

We are unable to present a quantitative reconciliation of our expected fully diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of provision for litigation, amortization of intangibles, merger and acquisition- related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, certain income tax net benefits from non-recurring tax adjustments, gains and losses from strategic investments, and the tax effects of all of the foregoing adjustments. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Income.

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward- looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company,” “Globus,” “Globus Medical,” “we,” “us,” and “our” refers to Globus Medical, Inc.

On November 2, 2026, our Board of Directors authorized the Company to repurchase an additional $500 million of shares of its common stock under our existing share repurchase program (the “Repurchase Program”), which does not have an expiration date. Repurchases under the Repurchase Program may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and actual number of shares repurchased under the Repurchase Program will be determined by management at its discretion and will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements and alternative investment opportunities. The Repurchase Program has no time limit and may be suspended for periods or discontinued at any time.

(In thousands, except share and per share values) ASSETS September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 441,272 $ 526,156 equivalents Short-term marketable 76,163 31,087 securities Accounts receivable, net of allowances 675,297 678,938 $47,866 and $33,434, respectively Inventories 824,144 759,277 Prepaid expenses and other current 116,437 65,426 assets Income taxes 48,651 64,727 receivable Total current assets 2,181,964 2,125,611 Property and 532,760 564,452 equipment, net Operating lease right 56,768 63,786 of use assets Long-term marketable 353,738 71,819 securities Intangible assets, 667,468 745,064 net Goodwill 1,453,561 1,435,033 Other assets 75,993 78,781 Deferred income taxes 205,941 218,215 Total assets $ 5,528,193 $ 5,302,761 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 107,428 $ 98,852 Accrued expenses 326,858 333,586 Operating lease 14,176 14,738 liabilities Income taxes payable 5,844 4,155 Business acquisition 25,820 19,513 liabilities Deferred revenue 27,812 27,655 Total current 507,938 498,499 liabilities Business acquisition liabilities, net of 80,547 81,995 current portion Operating lease 93,378 103,918 liabilities Deferred income taxes and other tax 31,603 23,756 liabilities Other liabilities 18,477 21,343 Total liabilities 731,943 729,511 Equity: Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 110 113 110,235,170 and 112,625,126 shares at September 30, 2026 and December 31, 2025, respectively Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22 22 22,430,097 and 22,430,097 shares at September 30, 2026 and December 31, 2025, respectively Additional paid-in 3,259,292 3,169,812 capital Accumulated other comprehensive 11,336 15,346 income/(loss) Retained earnings 1,525,490 1,387,957 Total equity 4,796,250 4,573,250 Total liabilities and $ 5,528,193 $ 5,302,761 equity

(In thousands) Nine Months Ended Cash flows from operating September 30, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 417,042 $ 397,274 Adjustments to reconcile net income to net cash provided by operating activities: Bargain purchase gain -1,118 -114,361 Depreciation and 209,730 207,357 amortization Provision for excess and obsolete 14,671 15,988 inventory Amortization of acquisition accounting — 19,631 fair value step up Stock-based compensation 37,743 38,361 expense Allowance for expected 13,954 5,311 credit losses Change in fair value of business 16,231 2,668 acquisition liabilities Change in deferred income 24,778 525 taxes (Gain)/loss on disposal of 6,765 8,438 assets, net Payment of business acquisition-related -2,965 -16,425 liabilities Net (gain)/loss from foreign currency 277 -14,621 adjustment (Increase) decrease in: Accounts receivable -12,345 11,971 Inventories -60,086 -17,420 Prepaid expenses and other 3,826 -6,689 assets Increase (decrease) in: Accounts payable 6,664 -654 Accrued expenses and other -15,375 25,442 liabilities Income taxes 17,540 -57,936 payable/receivable Net cash provided by/(used in) operating 677,332 504,860 activities Cash flows from investing activities: Purchases of marketable -398,841 -37,109 securities Sales and maturities of marketable 66,805 174,238 securities Purchases of property and -113,172 -118,482 equipment Acquisition of businesses, net of cash acquired and purchases of -22,417 -262,212 intangible and other assets Net cash provided by/(used in) investing -467,625 -243,565 activities Cash flows from financing activities: Payment of business acquisition-related -17,417 -11,240 liabilities Net proceeds from exercise of stock 52,812 26,999 options Payments related to tax withholdings for -3,453 -2,698 share-based compensation Repurchase of common stock -279,001 -255,451 Repayment of senior — -449,985 convertible notes Net cash provided by/(used in) financing -247,059 -692,375 activities Effect of foreign exchange -1,117 18,411 rates on cash Net increase/(decrease) in cash, cash -38,469 -412,669 equivalents, and restricted cash Cash, cash equivalents, and restricted 526,156 784,438 cash at beginning of period Cash, cash equivalents, and restricted $ 487,687 $ 371,769 cash at end of period Supplemental disclosures of cash flow information: Income taxes paid, net $ 65,804 $ 95,096 Non-cash investing and financing activities: Accrued purchases of property and $ 12,209 $ 13,454 equipment

The following table provides a reconciliation of cash and cash equivalents reported on our condensed consolidated balance sheets to the total of the cash, cash equivalents, and restricted cash reported within our condensed consolidated statements of cash flows.

As of September (In thousands) 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents shown in the $ 441,272 $ 371,769 condensed consolidated balance sheets Restricted escrow deposits included in 46,415 — prepaid expenses and other current assets Total cash, cash equivalents, and restricted cash shown in the $ 487,687 $ 371,769 condensed consolidated statements of cash flows

(1) Merger and acquisition-related costs represent certain costs associated with acquisitions. These costs, presented on a before-tax effect basis, are included in Non-GAAP Merger and Acquisition-related Costs Table. Non-GAAP Merger and Acquisition-related Costs Table:

(b) Primarily comprised of severance, share-based compensation and termination fees. Non-GAAP Net Income Reconciliation Table:

(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table for the detail of these costs. Non-GAAP Gross Profit Reconciliation Table:

(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail of these costs.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
 Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million 
                    Increase to the Share Repurchase Program                    
AUDUBON, PA., November 5, 2026: Globus Medical, Inc. (NYSE: GMED), a leading
musculoskeletal technology company, today announced its financial results for
the third quarter ended September 30, 2026.
                                                                                
  Third Quarter 2026 Results                                                    
                                                                                
• Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of
0.5% on a constant currency basis.

• Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an
increase of 3.0%, as reported.

• GAAP net income for the quarter was $141.2 million.

• GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. Non-
GAAP diluted EPS was $1.23, an increase of 4.4%.

• GAAP gross profit as a percentage of net sales was 66.7%, an increase of 2.5%.
Non-GAAP adjusted Gross Profit as a percentage of sales was 69.5%, an increase
of 1.4%.
“Third quarter revenue finished at $764 million, down slightly from the prior
year quarter,” commented Keith Pfeil, President and Chief Executive Officer.
“U.S. Spine faced difficult prior year comparables, growing 2% in the third
quarter, as compared to double digit growth in the prior year quarter. On an
average two-year basis, the U.S. Spine business is growing mid-single digits,
reflecting our ability to capture share in the market, as we lead with
innovation and differentiation. Our Enabling Technologies strategy continued to
make progress, delivering revenue growth of 24%, while simultaneously deploying
73% more robot and navigation units as compared to the prior year quarter,
reflecting continued strong demand for our technology and execution against our
capital deployment plan. We remain focused on our long-term strategy of
achieving improved surgical outcomes through the Globus ecosystem, bringing
together patient selection, surgical techniques with complementary implants and
technology to drive the surgical procedure, through a closed-loop surgical
intelligence ecosystem.”

“Our third quarter results highlight our Company’s commitment to delivering
consistent adjusted gross profit margin expansion, bottom-line profit, and free
cash flow generation, as we delivered the eighth straight quarter of sequential
adjusted gross profit margin expansion and record quarterly operating cash flow
and free cash flow generation,” said Kyle Kline, Chief Financial Officer. “Our
performance reflects disciplined execution across the business, which positions
us to deliver sustained earnings growth, cash generation, and enhanced
shareholder returns. To further this commitment, our Board has authorized a $500
million increase to our existing share repurchase program, which reflects
confidence in our long-term growth profile and underlying earnings and cash
generation prowess.”

Worldwide net sales for the third quarter of 2026 were $763.7 million, an as-
reported decrease of 0.7% over the third quarter of 2025. U.S. net sales for the
third quarter of 2026 increased by 0.5% compared to the third quarter of 2025.
International net sales decreased by 5.7% over the third quarter of 2025 on an
as-reported basis and decreased by 5.0% on a constant currency basis.

GAAP net income for the third quarter of 2026 was $141.2 million, an increase of
18.7% over the same period in the prior year. The increase in GAAP net income
was primarily driven by the decrease in cost of sales and operating expenses,
decreasing $19.6 million and $25.9 million, respectively, in comparison to the
third quarter of 2025. GAAP diluted EPS for the third quarter was $1.04,
compared to $0.88 for the third quarter of 2025, an increase of 18.2%. Non-GAAP
diluted EPS for the third quarter of 2026, which excludes, among other costs,
amortization of intangibles, merger and acquisition-related costs, and
restructuring-related costs, was $1.23, compared to $1.18 in the third quarter
of 2025, an increase of 4.4%.
                                                                                
  2026 Annual Guidance                                                          
                                                                                
The Company is updating its guidance for full-year 2026 revenue to $3.09 billion
from the previous range of $3.18 billion to $3.22 billion, representing 5.1%
revenue growth as compared to fiscal 2025. The Company reaffirms its full-year
fiscal 2026 non-GAAP fully diluted EPS guidance to be in the range of $4.95 to
$5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully
diluted EPS.
                                                                                
  Conference Call Information                                                   
                                                                                
Globus Medical will hold a teleconference to discuss its 2026 third quarter
results with the investment community at 4:30 p.m. Eastern Time today.
Participants may access the conference call live via webcast on the Investors
page of Globus Medical’s website at http://www.investors.globusmedical.com/news-
events/events-webcasts.

To participate via telephone, please register in advance at this link. Upon
registration, all telephone participants will receive a confirmation email
detailing how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access the call.
The audio archive will be available after the call on the Investor page of the
Globus Medical website.
                                                                                
  About Globus Medical, Inc.                                                    
                                                                                
Globus Medical, Inc. is a leading global musculoskeletal technology company
dedicated to solving unmet clinical needs and changing lives. We innovate with
inspired urgency, provide world-class education and clinical support, and
advance care throughout spine, orthopedic trauma, joint reconstruction,
biomaterials and enabling technologies. Additional information can be accessed
at www.globusmedical.com.
                                                                                
  Non-GAAP Financial Measures                                                   
                                                                                
To supplement our financial statements prepared in accordance with U.S.
generally accepted accounting principles (“GAAP”), management uses certain non-
GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents
net income before interest income, net and other non-operating expenses,
provision for income taxes, depreciation and amortization, stock-based
compensation expense, provision for litigation, merger and acquisition related
costs, restructuring related costs, certain foreign currency acquisition-related
impacts, bargain purchase gains, and gains and losses from strategic
investments, is useful as an additional measure of operating performance, and
particularly as a measure of comparative operating performance from period to
period, as it is reflective of changes in pricing decisions, cost controls and
other factors that affect operating performance, and it removes the effect of
our capital structure, asset base, income taxes and interest income and expense.
We no longer include acquisition of in-process research and development as an
adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP
Adjusted EBITDA for planning purposes, including the preparation of our annual
operating budget and financial projections. Provision for litigation represents
costs incurred for litigation settlements or unfavorable verdicts when the loss
is known or considered probable and the amount can be reasonably estimated, or
in the case of a favorable settlement, when income is realized. Merger and
acquisition related costs represent the change in fair value of business-
acquisition-related contingent consideration; costs related to integrating
recently acquired businesses, including but not limited to costs to exit or
convert contractual obligations, severance, retention bonus, duplicative costs
and information system conversion; and specific costs related to the
consummation of the acquisition process such as banker fees, legal fees, and
other acquisition related professional fees. Restructuring related costs include
severance, retention bonus, accelerated stock-based compensation expense, legal
and tax fees for legal entity reorganization and costs associated with
consolidating facilities. We also adjusted for certain foreign currency impacts
related to the acquisition costs and gains/losses on strategic investments
within other assets as we believe these impacts are not a measure of our
operating performance.

In addition, for the period ended September 30, 2026 and for other comparative
periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which
represent net income and diluted EPS excluding the provision for litigation,
amortization of intangibles, merger and acquisition related costs, restructuring
related costs, certain foreign currency impacts, gains and losses from strategic
investments, bargain purchase gains, certain income tax net benefits and non-
recurring tax adjustments, and the tax effects of all of the foregoing
adjustments. We no longer include acquisition of in-process research and
development as an adjustment to non-GAAP net income. We also present non-GAAP
adjusted gross profit, which excludes the impacts of any inventory acquisition-
related costs within cost of goods sold. The tax effect adjustment represents
the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net
income. The tax impact of the non-GAAP adjustments is calculated based on the
consolidated effective tax rate on a GAAP basis, applied to the non-GAAP
adjustments, unless the underlying item has a materially different tax
treatment, in which case the estimated tax rate applicable to the adjustment is
used. We believe these non-GAAP measures are also useful indicators of our
operating performance, and particularly as additional measures of comparative
operating performance from period to period as they remove the effects of the
foregoing items, which we believe are not reflective of underlying business
trends.

Additionally, for the period ended September 30, 2026 and for other comparative
periods, we also define the non-GAAP measure of free cash flow as the net cash
provided by operating activities, adjusted for the impact of restricted cash,
less the cash impact of purchases of property and equipment. We believe that
this financial measure provides meaningful information for evaluating our
overall financial performance for comparative periods as it facilitates an
assessment of funds available to satisfy current and future obligations and fund
acquisitions. Furthermore, the non-GAAP measure of constant currency net sales
growth is calculated by translating current year net sales at the same average
exchange rates in effect during the applicable prior year period. We believe
constant currency net sales growth provides insight to the comparative increase
or decrease in period net sales, in dollar and percentage terms, excluding the
effects of fluctuations in foreign currency exchange rates. We are also
presenting base business sales and revenue growth, excluding the contribution
from Nevro Corp. (“Nevro”), which we acquired in 2025. We believe these provide
insight to how the Company is performing without the impact of the Nevro
acquisition.

Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP
adjusted gross profit, free cash flow, constant currency net sales growth, base
business revenue growth, and day-adjusted basis sales are not calculated in
conformity with GAAP. Non-GAAP financial measures have limitations as analytical
tools and should not be considered in isolation or as a substitute for financial
measures prepared in accordance with GAAP. These measures do not include certain
expenses that may be necessary to evaluate our liquidity or operating results.
Our definitions of these non-GAAP measures may differ from that of other
companies and therefore may not be comparable. The tables included in this
release reconcile the GAAP financial measures to the non-GAAP financial measures
discussed above for the three and nine months ended September 30, 2026 and 2025.

We are unable to present a quantitative reconciliation of our expected fully
diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with
reasonable certainty and without unreasonable effort the impact and timing of
provision for litigation, amortization of intangibles, merger and acquisition-
related costs, restructuring related costs, certain foreign currency
acquisition-related impacts, bargain purchase gains, certain income tax net
benefits from non-recurring tax adjustments, gains and losses from strategic
investments, and the tax effects of all of the foregoing adjustments. The
financial impact of these items is uncertain and is dependent on various
factors, including timing, and could be material to our Consolidated Statements
of Income.
                                                                                
  Safe Harbor Statements                                                        
                                                                                
All statements included in this press release other than statements of
historical fact are forward-looking statements and may be identified by their
use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other
similar terms. These forward-looking statements are based on our current
assumptions, expectations and estimates of future events and trends. Forward-
looking statements are only predictions and are subject to many risks,
uncertainties and other factors that may affect our businesses and operations
and could cause actual results to differ materially from those predicted. These
risks and uncertainties include, but are not limited to, the risks and costs
associated with health epidemics, pandemics and similar outbreaks, factors
affecting our quarterly results, our ability to manage our growth, our ability
to sustain our profitability, demand for our products, our ability to compete
successfully (including without limitation our ability to convince surgeons to
use our products and our ability to attract and retain sales and other
personnel), our ability to rapidly develop and introduce new products, our
ability to develop and execute on successful business strategies, our ability to
comply with laws and regulations that are or may become applicable to our
businesses, our ability to safeguard our intellectual property, our success in
defending legal proceedings brought against us, trends in the medical device
industry, general economic conditions, the successful integration of businesses
that we have acquired or may acquire in the future, and other risks. For a
discussion of these and other risks, uncertainties, and other factors that could
affect our results, refer to the disclosures contained in our most recent Annual
Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the
“SEC”), including the sections labeled “Risk Factors” and “Cautionary Note
Concerning Forward-Looking Statements,” and in our subsequent filings with the
SEC. These documents are available at www.sec.gov. Moreover, we operate in an
evolving environment. New risk factors and uncertainties emerge from time to
time and it is not possible for us to predict all risk factors and
uncertainties, nor can we assess the impact of all factors on our business or
the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are cautioned not to
place undue reliance on any forward-looking statements. Forward-looking
statements contained in this press release speak only as of the date of this
press release. Except as may be required by applicable law, we undertake no
obligation to update any forward-looking statements as a result of new
information, events or circumstances or other factors arising or coming to our
attention after the date hereof. As used herein, the “Company,” “Globus,”
“Globus Medical,” “we,” “us,” and “our” refers to Globus Medical, Inc.
                                                                                
  Share Repurchase Program                                                      
                                                                                
On November 2, 2026, our Board of Directors authorized the Company to repurchase
an additional $500 million of shares of its common stock under our existing
share repurchase program (the “Repurchase Program”), which does not have an
expiration date. Repurchases under the Repurchase Program may be made through
privately negotiated transactions or open market transactions, including
pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18
under the Securities Exchange Act of 1934, as amended. The timing and actual
number of shares repurchased under the Repurchase Program will be determined by
management at its discretion and will depend on a variety of factors, including
market price of the shares, general business and market conditions, applicable
legal requirements and alternative investment opportunities. The Repurchase
Program has no time limit and may be suspended for periods or discontinued at
any time.
                                                                                
                     GLOBUS MEDICAL, INC. AND SUBSIDIARIES                      
                                                                                
                                                                                
                       CONSOLIDATED STATEMENTS OF INCOME                        
                                                                                
                                  (unaudited)                                   
                                                                                
  (…                                                                            
  t…          Th…                                  Ni…                          
  e…          Mo…                                  Mo…                          
  p…          En…                                  En…                          
  s…          Se…                                  Se…                          
  a…    2026  30,          20…               2026  30,          20…             
 ────────────────────────────────────────────────────────────────────────────── 
  N…    $     76…          $    769…         $     2,…          $    2,1…       
  s…                                                                            
  C…                                                                            
  of                                                                            
  s…                                                                            
  a…                                                                            
  o…                                                                            
  e…                                                                            
  C…                                                                            
  of                                                                            
  s…                                                                            
  (…          23…               252…               70…               696…       
  of                                                                            
  a…                                                                            
  of                                                                            
  i…                                                                            
  R…                                                                            
  a…          34…               38,…               10…               111…       
  d…                                                                            
  S…                                                                            
  g…          28…               313…               87…               860…       
  a…                                                                            
  a…                                                                            
  A…                                                                            
  of          29…               29,…               88…               88,…       
  i…                                                                            
  A…          720               -2,…               18…               31,…       
  c…                                                                            
  R…          -43                358               7,…               13,…       
  c…                                                                            
  O…          17…               137…               51…               310…       
  i…                                                                            
  O…                                                                            
  i…                                                                            
  n…                                                                            
  I…                                                                            
  i…          8,…               1,4…               20…               3,8…       
  n…                                                                            
  F…                                                                            
  c…          -1…               -161               -4…               4,1…       
  t…                                                                            
  g…                                                                            
  B…                                                                            
  p…            —               3,8…               1,…               114…       
  g…                                                                            
  O…          -9…               1,5…               2,…               3,0…       
  i…                                                                            
  T…                                                                            
  o…          5,…               6,6…               19…               125…       
  i…                                                                            
  n…                                                                            
  I…                                                                            
  b…          18…               143…               53…               435…       
  i…                                                                            
  t…                                                                            
  I…                                                                            
  t…          42…               25,…               11…               38,…       
  p…                                                                            
  N…    $     14…          $    118…         $     41…          $    397…       
  i…                                                                            
  O…                                                                            
  c…                                                                            
  i…                                                                            
  n…                                                                            
  of                                                                            
  t…                                                                            
                                                                                
  U…                                                                            
  g…                                                                            
  on          -2…                 30               -3…                347       
  m…                                                                            
  s…                                                                            
  F…                                                                            
  c…          2,…                658               -2…               17,…       
  t…                                                                            
  g…                                                                            
  T…                                                                            
  o…                                                                            
  c…                                                                            
  i…          140                688               -4…               17,…       
  n…                                                                            
  of                                                                            
  t…                                                                            
  C…    $     14…          $    119…         $     41…          $    415…       
  i…                                                                            
  E…                                                                            
  p…                                                                            
  s…                                                                            
  B…    $     1.…          $    0.88         $     3.…          $    2.93       
  D…    $     1.…          $    0.88         $     3.…          $    2.90       
  W…                                                                            
  a…                                                                            
  s…                                                                            
  o…                                                                            
  B…               134…               13…               134…               13…  
  D…               136…               13…               137…               13…  
                                                                                
                                                                                
                     GLOBUS MEDICAL, INC. AND SUBSIDIARIES                      
                                                                                
                                                                                
                          CONSOLIDATED BALANCE SHEETS                           
                                                                                
                                  (unaudited)                                   
                                                                                
  (In thousands, except                                                         
  share and per share                                                           
  values)                                                                       
  ASSETS                   September 30,               December 31,             
  Current assets:          2026                        2025                     
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash            $                441,272    $               526,156  
  equivalents                                                                   
  Short-term marketable                      76,163                     31,087  
  securities                                                                    
  Accounts receivable,                                                          
  net of allowances                         675,297                    678,938  
  $47,866 and $33,434,                                                          
  respectively                                                                  
  Inventories                               824,144                    759,277  
  Prepaid expenses and                                                          
  other current                             116,437                     65,426  
  assets                                                                        
  Income taxes                               48,651                     64,727  
  receivable                                                                    
  Total current assets                    2,181,964                  2,125,611  
  Property and                              532,760                    564,452  
  equipment, net                                                                
  Operating lease right                      56,768                     63,786  
  of use assets                                                                 
  Long-term marketable                      353,738                     71,819  
  securities                                                                    
  Intangible assets,                        667,468                    745,064  
  net                                                                           
  Goodwill                                1,453,561                  1,435,033  
  Other assets                               75,993                     78,781  
  Deferred income taxes                     205,941                    218,215  
  Total assets             $              5,528,193    $             5,302,761  
  LIABILITIES AND                                                               
  EQUITY                                                                        
  Current liabilities:                                                          
  Accounts payable         $                107,428    $                98,852  
  Accrued expenses                          326,858                    333,586  
  Operating lease                            14,176                     14,738  
  liabilities                                                                   
  Income taxes payable                        5,844                      4,155  
  Business acquisition                       25,820                     19,513  
  liabilities                                                                   
  Deferred revenue                           27,812                     27,655  
  Total current                             507,938                    498,499  
  liabilities                                                                   
  Business acquisition                                                          
  liabilities, net of                        80,547                     81,995  
  current portion                                                               
  Operating lease                            93,378                    103,918  
  liabilities                                                                   
  Deferred income taxes                                                         
  and other tax                              31,603                     23,756  
  liabilities                                                                   
  Other liabilities                          18,477                     21,343  
  Total liabilities                         731,943                    729,511  
  Equity:                                                                       
  Class A common stock;                                                         
  $0.001 par value.                                                             
  Authorized                                                                    
  500,000,000 shares;                                                           
  issued                                                                        
  and outstanding                               110                        113  
  110,235,170 and                                                               
  112,625,126 shares at                                                         
  September 30, 2026                                                            
  and December 31,                                                              
  2025, respectively                                                            
  Class B common stock;                                                         
  $0.001 par value.                                                             
  Authorized                                                                    
  275,000,000 shares;                                                           
  issued                                                                        
  and outstanding                                22                         22  
  22,430,097 and                                                                
  22,430,097 shares at                                                          
  September 30, 2026                                                            
  and December 31,                                                              
  2025, respectively                                                            
  Additional paid-in                      3,259,292                  3,169,812  
  capital                                                                       
  Accumulated other                                                             
  comprehensive                              11,336                     15,346  
  income/(loss)                                                                 
  Retained earnings                       1,525,490                  1,387,957  
  Total equity                            4,796,250                  4,573,250  
  Total liabilities and    $              5,528,193    $             5,302,761  
  equity                                                                        
                                                                                
                                                                                
                     GLOBUS MEDICAL, INC. AND SUBSIDIARIES                      
                                                                                
                                                                                
                     CONSOLIDATED STATEMENTS OF CASH FLOWS                      
                                                                                
                                  (unaudited)                                   
                                                                                
  (In thousands)                 Nine Months Ended                              
  Cash flows from operating      September 30,                                  
  activities:                    2026                           2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                     $                   417,042    $      397,274  
  Adjustments to reconcile                                                      
  net income to                                                                 
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Bargain purchase gain                               -1,118          -114,361  
  Depreciation and                                   209,730           207,357  
  amortization                                                                  
  Provision for excess and                                                      
  obsolete                                            14,671            15,988  
  inventory                                                                     
  Amortization of acquisition                                                   
  accounting                                               —            19,631  
  fair value step up                                                            
  Stock-based compensation                            37,743            38,361  
  expense                                                                       
  Allowance for expected                              13,954             5,311  
  credit losses                                                                 
  Change in fair value of                                                       
  business                                            16,231             2,668  
  acquisition liabilities                                                       
  Change in deferred income                           24,778               525  
  taxes                                                                         
  (Gain)/loss on disposal of                           6,765             8,438  
  assets, net                                                                   
  Payment of business                                                           
  acquisition-related                                 -2,965           -16,425  
  liabilities                                                                   
  Net (gain)/loss from                                                          
  foreign currency                                       277           -14,621  
  adjustment                                                                    
  (Increase) decrease in:                                                       
  Accounts receivable                                -12,345            11,971  
  Inventories                                        -60,086           -17,420  
  Prepaid expenses and other                           3,826            -6,689  
  assets                                                                        
  Increase (decrease) in:                                                       
  Accounts payable                                     6,664              -654  
  Accrued expenses and other                         -15,375            25,442  
  liabilities                                                                   
  Income taxes                                        17,540           -57,936  
  payable/receivable                                                            
  Net cash provided by/(used                                                    
  in) operating                                      677,332           504,860  
  activities                                                                    
  Cash flows from investing                                                     
  activities:                                                                   
  Purchases of marketable                           -398,841           -37,109  
  securities                                                                    
  Sales and maturities of                                                       
  marketable                                          66,805           174,238  
  securities                                                                    
  Purchases of property and                         -113,172          -118,482  
  equipment                                                                     
  Acquisition of businesses,                                                    
  net of cash                                                                   
  acquired and purchases of                          -22,417          -262,212  
  intangible and                                                                
  other assets                                                                  
  Net cash provided by/(used                                                    
  in) investing                                     -467,625          -243,565  
  activities                                                                    
  Cash flows from financing                                                     
  activities:                                                                   
  Payment of business                                                           
  acquisition-related                                -17,417           -11,240  
  liabilities                                                                   
  Net proceeds from exercise                                                    
  of stock                                            52,812            26,999  
  options                                                                       
  Payments related to tax                                                       
  withholdings for                                    -3,453            -2,698  
  share-based compensation                                                      
  Repurchase of common stock                        -279,001          -255,451  
  Repayment of senior                                      —          -449,985  
  convertible notes                                                             
  Net cash provided by/(used                                                    
  in) financing                                     -247,059          -692,375  
  activities                                                                    
  Effect of foreign exchange                          -1,117            18,411  
  rates on cash                                                                 
  Net increase/(decrease) in                                                    
  cash, cash                                         -38,469          -412,669  
  equivalents, and restricted                                                   
  cash                                                                          
  Cash, cash equivalents, and                                                   
  restricted                                         526,156           784,438  
  cash at beginning of period                                                   
  Cash, cash equivalents, and                                                   
  restricted                     $                   487,687    $      371,769  
  cash at end of period                                                         
  Supplemental disclosures of                                                   
  cash flow                                                                     
  information:                                                                  
  Income taxes paid, net         $                    65,804    $       95,096  
  Non-cash investing and                                                        
  financing                                                                     
  activities:                                                                   
  Accrued purchases of                                                          
  property and                   $                    12,209    $       13,454  
  equipment                                                                     
                                                                                
The following table provides a reconciliation of cash and cash equivalents
reported on our condensed consolidated balance sheets to the total of the cash,
cash equivalents, and restricted cash reported within our condensed consolidated
statements of cash flows.
                                                                                
                                     As of September                            
                     (In thousands)  30,                    2026          2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash                                                                 
  equivalents shown                                                             
  in the                             $                   441,272    $  371,769  
  condensed                                                                     
  consolidated                                                                  
  balance sheets                                                                
  Restricted escrow                                                             
  deposits included                                                             
  in                                                      46,415             —  
  prepaid expenses                                                              
  and other current                                                             
  assets                                                                        
  Total cash, cash                                                              
  equivalents, and                                                              
  restricted cash                                                               
  shown in the                       $                   487,687    $  371,769  
  condensed                                                                     
  consolidated                                                                  
  statements of                                                                 
  cash flows                                                                    
                                                                                
                                                                                
                       Supplemental Financial Information                       
                                                                                
                         Net Sales by Product Category:                         
                                                                                
                     Three                              Nine                    
                    Months                            Months                    
                     Ended                             Ended                    
  (In             Septemb…                           Septem…                    
  thous…    2026       30,    2025             2026      30,    2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Muscu…    $      728,855    $     741,009    $     2,225,…    $     2,027,1…  
  Solut…                                                                        
  Enabl…            34,864           28,039           87,806            85,387  
  Techn…                                                                        
  Total                                                                         
  net       $      763,719    $     769,048    $     2,313,…    $     2,112,5…  
  sales                                                                         
                                                                                
                                                                                
                        Liquidity and Capital Resources:                        
                                                                                
                                                                                
  (In thousands)                     2026  September 30,    2025  December 31,  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents          $           441,272    $          526,156  
  Short-term marketable                           76,163                31,087  
  securities                                                                    
  Long-term marketable securities                353,738                71,819  
  Total cash, cash equivalents                                                  
  and                                $           871,173    $          629,062  
  marketable securities                                                         
                                                                                
The following tables reconcile GAAP to non-GAAP financial measures.
                 Non-GAAP Adjusted EBITDA Reconciliation Table:                 
                                                                                
              Th…                                  Ni…                          
  (…          Mo…                                  Mo…                          
  t…          En…                                  En…                          
  e…          Se…                                  Se…                          
  p…    2026  30,          20…               2026  30,          20…             
 ────────────────────────────────────────────────────────────────────────────── 
  N…    $     14…          $    118…         $     41…          $    397…       
  i…                                                                            
  I…                                                                            
  (…          -8…               -1,…               -2…               -3,…       
  n…                                                                            
  P…                                                                            
  f…          42…               25,…               11…               38,…       
  i…                                                                            
  t…                                                                            
  D…                                                                            
  a…          70…               71,…               21…               207…       
  a…                                                                            
  E…          24…               213…               72…               639…       
  S…                                                                            
  c…          11…               11,…               37…               37,…       
  e…                                                                            
  P…                                                                            
  f…          3,…               28,…               3,…               24,…       
  l…                                                                            
  n…                                                                            
  M…                                                                            
  a…          632               4,6…               18…               46,…       
  a…                                                                            
  c…                                                                            
  N…                                                                            
  (…                                                                            
  l…          911               -946               -2…               -2,…       
  f…                                                                            
  s…                                                                            
  i…                                                                            
  N…                                                                            
  a…                                                                            
  f…          -60               -3,…               -2…               -15…       
  c…                                                                            
  i…                                                                            
  R…          -4…               2,2…               8,…               22,…       
  c…                                                                            
  B…                                                                            
  p…            —               -3,…               -1…               -11…       
  g…                                                                            
  A…    $     26…          $    252…         $     78…          $    639…       
  E…                                                                            
  N…                                                                            
  i…                                                                            
  as                                                                            
  a                18.5               15…               18.0               18…  
  p…               %                  %                 %                  %    
  of                                                                            
  n…                                                                            
  s…                                                                            
  A…                                                                            
  E…                                                                            
  as                                                                            
  a                34.3               32…               34.0               30…  
  p…               %                  %                 %                  %    
  of                                                                            
  n…                                                                            
  s…                                                                            
                                                                                
(1) Merger and acquisition-related costs represent certain costs associated with
acquisitions. These costs, presented on a before-tax effect basis, are included
in Non-GAAP Merger and Acquisition-related Costs Table.
              Non-GAAP Merger and Acquisition-related Costs Table:              
                                                                                
                       Three                              Nine                  
                      Months                            Months                  
                       Ended                             Ended                  
  (In              September                          Septemb…                  
  thousa…    2026        30,    2025            2026       30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Amorti…                                                                       
  of                                                                            
  invent…    $             —    $      6,957    $            —    $     12,973  
  fair                                                                          
  value                                                                         
  step up                                                                       
  Change                                                                        
  in fair                                                                       
  value                                                                         
  of                     172          -2,721            16,231           2,681  
  busine…                                                                       
  acquis…                                                                       
  liabil…                                                                       
  Employ…                548               —             1,946          27,418  
  costs(…                                                                       
  Other                                                                         
  acquis…                -88             442               186           3,105  
  costs(…                                                                       
  Merger                                                                        
  and        $           632    $      4,678    $       18,363    $     46,177  
  acquis…                                                                       
  costs                                                                         
                                                                                
(a) Primarily comprised of legal fees, advisory and consulting fees.

(b) Primarily comprised of severance, share-based compensation and termination
fees.
                   Non-GAAP Net Income Reconciliation Table:                    
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
  (In              Septem…                           Septemb…                   
  thousa…    2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net        $     141,171    $     118,966    $      417,042    $     397,274  
  income…                                                                       
  Provis…                                                                       
  for                3,665           28,261             3,861           24,353  
  litiga…                                                                       
  net                                                                           
  Amorti…                                                                       
  of                29,574           29,843            88,660           88,834  
  intang…                                                                       
  Merger                                                                        
  and                  632            4,678            18,363           46,177  
  acquis…                                                                       
  costs(…                                                                       
  Net                                                                           
  gain/(…                                                                       
  on                   911             -946              -278           -2,255  
  strate…                                                                       
  invest…                                                                       
  Non-ca…                                                                       
  acquis…                                                                       
  foreign              -60           -3,045              -277          -15,382  
  curren…                                                                       
  impacts                                                                       
  Restru…             -473            2,260             8,674           22,909  
  costs                                                                         
  Bargain                                                                       
  purcha…                —           -3,800            -1,118          -114,3…  
  gain                                                                          
  Provis…                                                                       
  for                                                                           
  income                                                                        
  tax                                                                           
  benefit                —           -1,740                 —          -36,555  
  from                                                                          
  non-re…                                                                       
  tax                                                                           
  adjust…                                                                       
  Tax                                                                           
  effect                                                                        
  of                -8,378          -15,127           -28,695          -40,034  
  adjust…                                                                       
  items                                                                         
  Non-GA…                                                                       
  net        $     167,042    $     159,350    $      506,232    $     370,960  
  income…                                                                       
                                                                                
(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table for the
detail of these costs.
                  Non-GAAP Gross Profit Reconciliation Table:                   
                                                                                
         Thr…                                    Nine                           
         Mon…                                    Mon…                           
  (In    End…                                    End…                           
  th…    Sep…                                    Sep…                           
  ex…    30,                                     30,                            
  pe…    2026                2025                2026            2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net    $     763…          $     769…          $       2,3…    $       2,11…  
  sa…                                                                           
  Co…                                                                           
  of                                                                            
  sa…                                                                           
  (e…          232…                252…                  708…            696,…  
  of                                                                            
  am…                                                                           
  of                                                                            
  in…                                                                           
  Am…                                                                           
  of           21,…                22,…                  63,…            69,5…  
  in…                                                                           
  Gr…    $     509…          $     493…          $       1,5…    $       1,34…  
  Pr…                                                                           
  Am…                                                                           
  of                                                                            
  in…                                                                           
  fa…             —                6,9…                     —            12,9…  
  va…                                                                           
  st…                                                                           
  up                                                                            
  Am…                                                                           
  of           21,…                22,…                  63,…            69,5…  
  in…                                                                           
  Ad…                                                                           
  Gr…    $     530…          $     523…          $       1,6…    $       1,42…  
  Pr…                                                                           
  Gr…                                                                           
  Pr…                                                                           
  %                  66.7                64.2            66.6             63.7  
  of                 %                   %                  %                %  
  Net                                                                           
  Sa…                                                                           
  Ad…                                                                           
  Gr…                                                                           
  Pr…                69.5                68.1            69.4             67.6  
  %                  %                   %                  %                %  
  of                                                                            
  Net                                                                           
  Sa…                                                                           
                                                                                
           Non-GAAP Diluted Earnings Per Share Reconciliation Table:            
                                                                                
                        Three                              Nine                 
                       Months                            Months                 
  (Per                  Ended                             Ended                 
  share             September                         September                 
  amounts)    2026        30,    2025           2026        30,    2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Diluted                                                                       
  earnings                                                                      
  per         $          1.04    $      0.88    $          3.04    $      2.90  
  share,                                                                        
  as                                                                            
  reported                                                                      
  Provisi…                                                                      
  for                    0.03           0.21               0.03           0.18  
  litigat…                                                                      
  net                                                                           
  Amortiz…                                                                      
  of                     0.22           0.22               0.65           0.65  
  intangi…                                                                      
  Merger                                                                        
  and                       —           0.03               0.13           0.34  
  acquisi…                                                                      
  costs(1)                                                                      
  Net                                                                           
  (gain)                                                                        
  loss                   0.01          -0.01                  —          -0.02  
  from                                                                          
  strateg…                                                                      
  investm…                                                                      
  Non-cash                                                                      
  acquisi…                                                                      
  foreign                   —          -0.02                  —          -0.11  
  currency                                                                      
  impacts                                                                       
  Restruc…                  —           0.02               0.06           0.17  
  costs                                                                         
  Bargain                                                                       
  purchase                  —          -0.03              -0.01          -0.83  
  gain                                                                          
  Provisi…                                                                      
  for                                                                           
  income                                                                        
  tax                                                                           
  benefit                   —          -0.01                  —          -0.27  
  from                                                                          
  non-rec…                                                                      
  tax                                                                           
  adjustm…                                                                      
  Tax                                                                           
  effect                                                                        
  of                    -0.06          -0.11              -0.21          -0.29  
  adjusti…                                                                      
  items                                                                         
  Non-GAAP                                                                      
  diluted                                                                       
  earnings    $          1.23    $      1.18    $          3.69    $      2.70  
  per                                                                           
  share                                                                         
                                                                                
(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above
for the detail of these costs.

*Amounts may not add due to rounding.
                 Non-GAAP Free Cash Flow Reconciliation Table:                  
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
  (In              Septem…                           Septemb…                   
  thousa…    2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  provid…    $     265,227    $     249,696    $      677,332    $     504,860  
  by                                                                            
  operat…                                                                       
  activi…                                                                       
  Purcha…                                                                       
  of                                                                            
  proper…          -40,389          -35,817          -113,172          -118,4…  
  and                                                                           
  equipm…                                                                       
  Free                                                                          
  cash       $     224,838    $     213,879    $      564,160    $     386,378  
  flow                                                                          
                                                                                
       Non-GAAP Net Sales on a Constant Currency Basis Comparative Table:       
                                                                                
                                                        Curr…                   
                                                        Impa…                   
                 Three                                  on               Cons…  
         (In     Mont…                        Repor…    Curr…            Curr…  
         thous…  Ended                        Net       Peri…            Net    
         except  Sept…                        Sales     Net              Sales  
         perce…  30,      2026        2025    Growth    Sales            Grow…  
 ────────────────────────────────────────────────────────────────────────────── 
  Unit…          $      620,9…    $  617,…    0.5%      $           —    0.5%   
  Stat…                                                                         
  Inte…                 142,7…       151,…    -5.7%            -1,124    -5.0%  
  Total                                                                         
  net            $      763,7…    $  769,…    -0.7%     $      -1,124    -0.5%  
  sales                                                                         
                                                                                
                                                                                
                                                        Curr…                   
                                                        Impa…                   
                 Nine                                   on               Cons…  
         (In     Mont…                        Repor…    Curr…            Curr…  
         thous…  Ended                        Net       Peri…            Net    
         except  Sept…                        Sales     Net              Sales  
         perce…  30,      2026        2025    Growth    Sales            Grow…  
 ────────────────────────────────────────────────────────────────────────────── 
  Unit…          $      1,844…    $  1,70…    8.4%      $           —    8.4%   
  Stat…                                                                         
  Inte…                 468,2…       410,…    14.1%            10,430    11.6%  
  Total                                                                         
  net            $      2,313…    $  2,11…    9.5%      $      10,430    9.0%   
  sales                                                                         
                                                                                
         Base Business and Nevro Corp. Net Sales Reconciliation Table:          
                                                                                
                     Three                              Nine                    
                    Months                            Months                    
                     Ended                             Ended                    
  (In             Septemb…                           Septem…                    
  thous…    2026       30,    2025             2026      30,    2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  Sales                                                                         
  of        $       73,701    $      99,254    $     237,392    $      193,839  
  Nevro                                                                         
  produ…                                                                        
  Net                                                                           
  Sales                                                                         
  of               690,018          669,794          2,075,…          1,918,6…  
  base                                                                          
  busin…                                                                        
  Total                                                                         
  net       $      763,719    $     769,048    $     2,313,…    $     2,112,5…  
  sales                                                                         
                                                                                
Investor Contact:
Shagun Singh

Senior Vice President, Strategy and Investor Relations

Phone: (610) 930-1800

Email: [email protected]

www.globusmedical.com

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GMED/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.